BCL2 and cancer: ABT‐263 is a potent inhibitor of the Bcl‐2 family of anti‐apoptotic factors and is a promising chemotherapeutic drug for cancer cell treatment (Oltersdorf et al., 2005; Tse et al., 2008), but currently, ABT‐263 is considered a highly selective senolytic agent (Chang et al., 2016; Pan et al., 2017, 62).